Heterocyclic Compounds

Matches 351 - 400 out of 15,399	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/101981A1	SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...
WO/2023/102228A1	HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS Described herein are compounds of Formula l-A that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
WO/2023/102231A1	5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure...
WO/2023/097194A2	THERAPEUTIC COMPOUNDS AND METHODS OF USE This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
WO/2023/094304A1	MICROBIOCIDAL HETEROBIARYL AMIDE DERIVATIVES Compounds of Formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
WO/2023/096225A1	HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE AND COMPOSITION FOR FORMING ORGANIC MATERIAL LAYER, COMPRISING SAME The present specification relates to a heterocyclic compound of chemical formula 1, and an organic light-emitting device and a composition for forming an organic material layer, comprising same.
WO/2023/097204A1	MICROSPHERE FORMULATIONS COMPRISING ASENAPINE AND METHODS FOR MAKING AND USING THE SAME Microsphere formulations comprising asenapine are provided. Methods for making and using the microsphere formulations are also provided.
WO/2023/092231A1	ALPHA-1062 FOR TREATING TRAUMATIC BRAIN INJURY The invention relates to a pharmaceutical composition comprising a compound ALPHA-1062 or salt thereof, or to a compound ALPHA-1062 or salt thereof, for use in the treatment of confirmed or suspected traumatic brain injury (TBI) in a sub...
WO/2023/094594A1	SUBSTITUTED DIHYDROPYRANOPYRIDINES, SALTS OR N-OXIDES THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES The present invention relates to substituted dihydropyranopyridines of the general formula (I), salts or N-oxides thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to their...
WO/2023/092814A1	AMINO-SUBSTITUTED CHROMENOQUINOLINE TYPE FLUORESCENT MARKER, AND PREPARATION AND USE THEREOF An amino-substituted chromenoquinoline type fluorescent marker, and a preparation method therefor and the use thereof. The fluorescent marker is prepared by means of subjecting an amino group of an aromatic amine compound and two aldehyd...
WO/2023/091561A1	NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS The present invention discloses compounds of Formula (la), and pharmaceutically acceptable salts thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound ...
WO/2023/088996A1	SYNTHESIS OF 2'-(7,7-DIMETHYL-1'H,7H-SPIRO[FURO[3,4-B]PYRIDINE-5,4'-PIPERIDIN]-1'-YL)-1,3-DIH YDRO-4'H-SPIRO[INDENE-2,5'-[1,3]OXAZOL]-4'-ONE, AND CRYSTALLINE FORMS THEREOF The application relates to crystalline forms of the compound 2'-(7,7- dirnethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1 '-yl)-1,3- dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one (formula I) as well as to processes for the p...
WO/2023/088235A1	EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
WO/2022/164789A9	TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
WO/2023/087747A1	PREPARATION METHOD FOR HIV INHIBITOR AND INTERMEDIATE CRYSTALLINE FORM THEREOF Disclosed in the present invention are a preparation method for an HIV inhibitor and an intermediate crystalline form thereof. The reaction formula of the HIV inhibitor is as follows. The preparation method of the present invention has h...
WO/2023/088921A1	HERBICIDAL DERIVATIVES Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
WO/2023/088493A1	FURO-PYRIDONE COMPOUND AND USE THEREOF The present application provides a furo-pyridone compound and a use thereof. The furo-pyridone compound provided in the present application can selectively inhibit the combination of a BET family bromodomain and acetylated lysine, can be...
WO/2023/088408A1	SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF A selective PARP1 inhibitor and an application thereof. Provided are a compound represented by general formula (I-A), and a stereoisomer, a pharmaceutically acceptable salt or a deuterated compound thereof. Also provided are a pharmaceut...
WO/2023/088406A1	FUSED IMIDE DERIVATIVE Provided are a fused imide derivative as shown in formula I, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the treatment of relevant diseases (such as cancers).
WO/2023/090288A1	COMPOUND, LIGHT-EMITTING MATERIAL AND LIGHT-EMITTING ELEMENT This organic light-emitting element in which a compound represented by the general formula is used exhibits excellent light-emitting characteristics. R1 represents a hydrogen atom, a deuterium atom, or an alkyl group, R2-R4 each represen...
WO/2023/085877A1	COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME The present specification relates to a compound of chemical formula 1, and an organic light-emitting element comprising same.
WO/2023/085834A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention provides a novel compound and an organic light-emitting device comprising same.
WO/2023/085835A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME The present invention provides a novel compound and an organic light-emitting device using same.
WO/2023/085860A1	COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound of chemical formula 1, and an organic light-emitting device comprising same.
WO/2023/085789A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention provides a novel compound and an organic light-emitting device comprising same.
WO/2023/085420A1	FERROPTOSIS INHIBITOR AND USE THEREFOR The present invention provides a means whereby it is possible to clarify the mechanism of manifestation of symptoms, an illness, or dysfunction caused by mitochondrial dysfunction and prevent or treat symptoms, an illness, or dysfunction...
WO/2023/081730A1	4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER The present invention relates to 82 specific 4-hydroxy-2-oxo-1,2- dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid CB2 receptor modulators for the treatment of cancer, e.g. to 6-(4- fluorophenyl)-4-hydroxy-1-(2-(4-methy...
WO/2023/081209A1	PI3K INHIBITORS AND METHODS OF TREATING CANCER Compounds of Formula (I) and pharmaceutically active salts thereof are provided, where the variables in Formula (I) are described herein. Such compounds and salts are PI3K inhibitors that are useful for treating conditions characterized ...
WO/2023/078812A1	BENZOFURO[3,2-D]PYRIMIDINO-2,4-DICARBONITRIL DERIVATIVES AND SIMILAR COMPOUNDS FOR ORGANIC ELECTROLUMINESCENCE DEVICES The present invention relates to dicyano-substituted monoaza- or diazadibenzofurane derivatives and dicyano-substituted monoaza- or diazadibenzothiophene derivatives of the formula (1), wherein the following applies to the symbols and in...
WO/2023/077910A1	CURING AGENT, CURING AGENT COMPOSITION AND PREPARATION METHOD THEREFOR The present invention provides a preparation method for a curing agent composition, comprising the following steps: providing a first component and a second component; and mixing the first component and the second component, heating the ...
WO/2023/079993A1	COMPOUND, COMPOSITION, HOST MATERIAL, AND ORGANIC ELECTROLUMINESCENT ELEMENT An organic electroluminescent element having excellent properties can be provided by using a compound of the general formula. X represents O or S and R1 to R6 each represent H, D, an alkyl group, or an aryl group. Z1 and/or Z2 is a benzo...
WO/2023/072945A1	PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS Compounds of the formula (I),wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...
WO/2023/070199A1	USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] TO AMELIORATE PROTEASOME INHIBITOR RESISTANCE Methods and corresponding uses are provided for treating disease in a patient, involving the use of sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] so as to ameliorate drug resistance, including resistance to proteasome inhibi...
WO/2023/077070A1	RXFP1 AGONISTS The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
WO/2023/076534A1	DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS Disclosed are compounds that can be converted to mesembrenone under biologically relevant conditions, such as acid hydrolysis at body temperature; and related methods of preparing and using these compounds. Stable preparations of isolate...
WO/2023/071314A1	SYNTHESIS, PREPARATION METHOD AND USE OF SHP2 AND CDK4/6 DUAL-TARGET INHIBITORY COMPOUND The present invention belongs to the field of medicinal chemistry, and particularly relates to synthesis, a preparation method and the use of an inhibitor containing dual targets SHP2 and CDK4/6, wherein the inhibitor comprises three com...
WO/2023/076849A1	INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR Disclosed herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that are inhibitors of inhibitors of epidermal growth factor receptor (EGFR), including EGFR C797S mutants. Also disclosed herein are pharmaceu...
WO/2023/072143A1	CAMPTOTHECIN DERIVATIVE INTERMEDIATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are a camptothecin derivative intermediate, and a preparation method therefor and the use thereof. The structural formula of the camptothecin derivative intermediate of the present invention is as shown...
WO/2023/014979A9	CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS Provided herein are radiopharmaceutical compositions, conjugates and uses thereof. In one aspect, provided herein are covalently modified KRAS proteins comprising a radiolabeled compound or conjugate. In some embodiments, the radiolabele...
WO/2023/069708A1	COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF Described herein, in part, are compounds that bind to and modulate the surface of cereblon and mediate the degradation of GSPT1, and are therefore useful in the treatment of various disorders, such as cancer.
WO/2023/066377A1	NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF A compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The nitrogen-co...
WO/2023/061477A1	NEW CRYSTAL FORM OF NITROGEN-CONTAINING TRICYCLIC COMPOUND AND USE THEREOF A new crystal form of a nitrogen-containing tricyclic compound and a use thereof, relating to a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methox y)-10H-spiro[benzo[6,7]oxazepine[3,2-b]pyridine-11,1'-cyclop...
WO/2023/064587A1	7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS The present invention relates to 7,8-dihydro-5H-l,6-naphthyridine derivatives of formula (I) The present compounds are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in treating neurological...
WO/2023/061998A1	MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES The present invention relates to diazabenzofurocarbazole derivatives and diazabenzothieonocarbazole derivatives and to electronic devices containing said compounds, in particular organic electroluminescent devices containing said compoun...
WO/2023/060362A1	RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, f...
WO/2023/063761A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME The present invention provides a novel compound and an organic light-emitting device using same.
WO/2023/061468A1	NEW CRYSTAL FORM AND USE OF NITROGENOUS TRICYCLIC COMPOUND Provided are a new crystal form and use of a nitrogenous tricyclic compound in the field of drugs. Specifically, the present invention relates to a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)metho xy)-10H-...
WO/2023/061473A1	NEW CRYSTAL FORM OF NITROGEN-CONTAINING TRICYCLIC COMPOUND AND USE THEREOF Disclosed is a new crystal form of compound 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)metho xy)-10H-spiro[benzo[6],7]oxazepine[3,2-b]pyridine-11,1'-cycl opropane]-7-formic acid. The new crystal form is crystal form J. Furthe...
WO/2023/063697A1	NOVEL CAPSID ASSEMBLY INHIBITORS The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.
WO/2023/061463A1	NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF A pyrimidopyridine compound, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a compound represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a met...

Matches 351 - 400 out of 15,399	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >